Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes

DOI PDF Web Site 被引用文献5件 参考文献4件 オープンアクセス
  • Tadashi Imafuku
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Hiroshi Watanabe
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Kentaro Oniki
    Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Akira Yoshida
    Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan
  • Hiromasa Kato
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Takehiro Nakano
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Kai Tokumaru
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Issei Fujita
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Nanaka Arimura
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Hitoshi Maeda
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Yuki Sakamoto
    Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Nozomi Kondo
    Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Ayami Morita
    Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan
  • Junji Saruwatari
    Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
  • Motoko Tanaka
    Department of Nephrology, Akebono Clinic, Kumamoto, Japan
  • Kazutaka Matsushita
    Department of Nephrology, Akebono Clinic, Kumamoto, Japan
  • Takashi Wada
    Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Masafumi Fukagawa
    Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan
  • Masaki Otagiri
    Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
  • Michael L. Fitzgerald
    Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA
  • Hideaki Jinnouchi
    Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan
  • Toru Maruyama
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

収録刊行物

  • Diabetes Care

    Diabetes Care 44 (6), e115-e117, 2021-04-26

    American Diabetes Association

被引用文献 (5)*注記

もっと見る

参考文献 (4)*注記

もっと見る

関連プロジェクト

もっと見る

問題の指摘

ページトップへ